CXCL12 (chemokine (C-X-C motif) ligand 12) [PDF]
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2017 Review on CXCL12, with data on DNA, on the protein encoded, and where the gene is implicated.
Giulia Gentile +2 more
openaire +6 more sources
Chemokine (C-X-C Motif) Ligand 12 Is Associated with Gallbladder Carcinoma Progression and Is a Novel Independent Poor Prognostic Factor [PDF]
Clinical Cancer Research, 2012 Abstract Purpose: Although recent studies have suggested that chemokine (C-X-C motif) ligand 12 (CXCL12) is important in the progression of various malignancies, its role in gallbladder carcinoma (GBC) remains unknown. We investigated CXCL12 expression in GBC and its biologic and prognostic role in GBC tumorigenesis.
Hyun Jung, Lee +12 more
openaire +3 more sources
Stromal Cell–Derived Factor-1/Chemokine (C-X-C Motif) Ligand 12 Stimulates Human Hepatoma Cell Growth, Migration, and Invasion [PDF]
Molecular Cancer Research, 2007 AbstractIn addition to their physiologic effects in inflammation and angiogenesis, chemokines are involved in cancer pathology. The aim of this study was to determine whether the chemokine stromal cell–derived factor 1 (SDF-1) induces the growth, migration, and invasion of human hepatoma cells.
Sutton, A. +13 more
openaire +5 more sources
A new clinical prognostic nomogram for liver cancer based on immune score. [PDF]
PLoS ONE, 2020 BackgroundIncreased attention is being paid to the relationship between the immune status of the tumor microenvironment and tumor prognosis. The application of immune scoring in evaluating the clinical prognosis of liver cancer patients has not yet been ...
Qinyan Shen +3 more
doaj +2 more sources
Collagen content and C-X-C motif chemokine ligand 12 expression in neoplastic breast stroma. [PDF]
Rev Assoc Med Bras (1992), 2023 This study aimed to evaluate the expression of C-X-C motif chemokine ligand 12 and its C-X-C chemokine receptor type 4, and the tumor-stroma ratio using collagen stromal content of breast cancer samples, correlating it with clinicopathological data.Through a retrospective cohort study, samples were obtained from female patients, over 18 years of age ...
Ferreira CJDS +3 more
europepmc +4 more sources
The Chemokine Receptor CXCR4 and c-MET Cooperatively Promote Epithelial-Mesenchymal Transition in Gastric Cancer Cells [PDF]
Translational Oncology, 2018 The C-X-C motif chemokine receptor 4 (CXCR4) pathway can promote tumor metastasis but is dependent on cross talk with other signaling pathways. The MET proto-oncogene (c-MET) participates in metastasis and is highly expressed in gastric cancer.
Yu Cheng +12 more
doaj +2 more sources
C-X-C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy. [PDF]
Bioengineered, 2021 Duchenne muscular dystrophy (DMD) is an X-linked recessive disease caused by a mutant dystrophin protein. DMD patients undergo gradual progressive paralysis until death. Chronic glucocorticoid therapy remains one of the main treatments for DMD, despite the significant side effects. However, its mechanisms of action remain largely unknown.
Lai X, Chen J.
europepmc +4 more sources
C‑X‑C receptor 7 agonist acts as a C‑X‑C motif chemokine ligand 12 inhibitor to ameliorate osteoclastogenesis and bone resorption. [PDF]
Mol Med Rep, 2022 The C‑X‑C receptor (CXCR) 7 agonist, VUF11207, is a chemical compound that binds specifically to CXCR7, and negatively regulates C‑X‑C motif chemokine ligand 12 (CXCL12) and CXCR4‑induced cellular events. Lipopolysaccharide (LPS) can induce inflammatory cytokines and pathological bone loss.
Nugraha AP +9 more
europepmc +4 more sources
New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM [PDF]
Vaccines, 2020 Deciphering the molecular alterations leading to disease initiation and progression is currently crucial to identify the most relevant targets for precision therapy in cancer patients.
Stefania Scala +7 more
doaj +3 more sources
The Heterogeneity and Function of Stromal Cells in the Tumor Microenvironment [PDF]
ResearchThe tumor microenvironment is a central determinant of cancer progression, metastatic spread, and therapeutic resistance. Once considered passive scaffolds, stromal cells are now recognized as heterogeneous, active regulators of tumor behavior.
Xuehai Wang +6 more
doaj +2 more sources